The European Medicines Agency is this week deciding whether to recommend pan-EU marketing approval for a number of new medicines including the investigational relugolix-based combination tablet from Myovant Sciences for treating uterine fibroids.
The potential uterine fibroids therapy is one of six new medicines that are listed on the agenda of the...








